Great Novel Therapeutics Biotech & Medicals (ROCO:7427) EPS (Basic) : NT$-1.64 (TTM As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Great Novel Therapeutics Biotech & Medicals EPS (Basic)?

Great Novel Therapeutics Biotech & Medicals's basic earnings per share (Basic EPS) for the six months ended in Dec. 2023 was NT$-0.68. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Dec. 2023 was NT$-1.64.

Great Novel Therapeutics Biotech & Medicals's EPS (Diluted) for the six months ended in Dec. 2023 was NT$-0.68. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was NT$-1.64.

Great Novel Therapeutics Biotech & Medicals's EPS without NRI for the six months ended in Dec. 2023 was NT$-0.68. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2023 was -1.64.

During the past 3 years, the average EPS without NRI Growth Rate was 0.70% per year. During the past 5 years, the average EPS without NRI Growth Rate was 6.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 6 years, Great Novel Therapeutics Biotech & Medicals's highest 3-Year average EPS without NRI Growth Rate was 18.50% per year. The lowest was -6.00% per year. And the median was 0.70% per year.

Great Novel Therapeutics Biotech & Medicals EPS (Basic) Historical Data

The historical data trend for Great Novel Therapeutics Biotech & Medicals's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Great Novel Therapeutics Biotech & Medicals EPS (Basic) Chart

Great Novel Therapeutics Biotech & Medicals Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EPS (Basic)

Get a 7-Day Free Trial

-1.87

-1.67

-1.49

-2.22

-1.64

Great Novel Therapeutics Biotech & Medicals Semi-Annual Data
	Dec18	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
EPS (Basic)	Get a 7-Day Free Trial					-0.73	-1.22	-1.00	-0.95	-0.68

Great Novel Therapeutics Biotech & Medicals EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Great Novel Therapeutics Biotech & Medicals's Basic EPS for the fiscal year that ended in Dec. 2023 is calculated as

Basic EPS (A: Dec. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-61.54	-	0)	/	37.721
	=	-1.63

Great Novel Therapeutics Biotech & Medicals's Basic EPS for the quarter that ended in Dec. 2023 is calculated as

Basic EPS (Q: Dec. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-27.492	-	0)	/	39.865
	=	-0.69

EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was NT$-1.64

Great Novel Therapeutics Biotech & Medicals (ROCO:7427) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Great Novel Therapeutics Biotech & Medicals EPS (Basic) Related Terms

Thank you for viewing the detailed overview of Great Novel Therapeutics Biotech & Medicals's EPS (Basic) provided by GuruFocus.com. Please click on the following links to see related term pages.

Great Novel Therapeutics Biotech & Medicals (ROCO:7427) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Great Novel Therapeutics Biotech & Medicals (ROCO:7427) » Definitions » EPS (Basic)

Comparable Companies

Traded in Other Exchanges

N/A

Address

No.3, Park Street, Room WR-06, 17th Floor, Nangang District, Taipei, TWN, 11503

Website

http://www.gntbm.com.tw

Great Novel Therapeutics Biotech & Medicals focuses on drug development to treat advanced cancer. The new drugs ranging from epigenetic modulators, a combination of tumor microenvironment-regulating agents, epigenetic immuno-modulators, to the protein degradation drugs targeting HDACs 1, 2, and 3, are in a developing pipeline. These drugs focus on the field of epigenetics, for the demand of clinical unmet needs in advanced and refractory cancers.

Great Novel Therapeutics Biotech & Medicals (ROCO:7427) Headlines

No Headlines